Morepen Laboratories Shares Plummet 5% as Q4 Earnings Decline 48% QoQ; Announces 10% Final Dividend 

Synopsis: Morepen Laboratories Ltd reported a mixed Q4 FY26 performance with stable revenue growth but pressure on profitability and margins. The company also announced a final dividend of Rs. 0.20 per equity share for FY26. Despite steady sales growth, lower operating margins and higher tax expenses impacted the company’s bottom-line performance during the quarter. 

Morepen Laboratories Ltd  is a pharmaceutical and healthcare company engaged in the manufacturing of APIs, formulations, diagnostics, and home healthcare products. The company has a strong presence across domestic and international markets with exports contributing significantly to overall revenue. The company operates in therapeutic categories including diabetes, cardiovascular, pain management, and wellness products.

Morepen Laboratories Ltd  currently has a market capitalization of around Rs. 2,312 crore, while the stock trades near Rs. 42.2 down by 5% compared to its previous close of Rs. 44. The stock has touched a 52-week high of Rs. 70.5 and a low of Rs. 33. Morepen Laboratories has reported ROCE of 8.05% and ROE of 6.20%, while the company’s book value stands at Rs. 22.8 per share. 

Morepen Laboratories reported revenue from operations of Rs. 485 crore in Q4 FY26, compared to Rs. 484 crore in Q3 FY26, reflecting marginal sequential growth. On a year-on-year basis, revenue increased by around 4.1% from Rs. 466 crore reported in Q4 FY25. 

The company posted an operating profit of Rs. 24 crore during Q4 FY26, compared to Rs. 46 crore in Q3 FY26, reflecting a sequential decline of around 47.8%. On a yearly basis, operating profit also declined sharply from Rs. 42 crore reported in Q4 FY25. Operating profit margins came in at 5% during the quarter, compared to 10% in Q3 FY26 and 9% in Q4 FY25.

Profit before tax stood at Rs. 23 crore in Q4 FY26, compared to Rs. 35 crore in Q3 FY26 and Rs. 26 crore in Q4 FY25. Net profit for the quarter came in at Rs. 16 crore, registering a decline from Rs. 28 crore reported in Q3 FY26 and Rs. 20 crore reported in Q4 FY25. The decline in earnings was mainly due to weaker operating margins and higher tax expenses during the quarter. 

The board of directors recommended a final dividend of Rs. 0.20 per equity share having a face value of Rs. 2 each for FY26, subject to shareholder approval at the upcoming Annual General Meeting. 

Industry Outlook 

India’s pharmaceutical industry continues to benefit from rising healthcare spending, increasing exports, and strong government support through PLI schemes and API manufacturing incentives. India currently ranks among the world’s largest producers of generic medicines and pharmaceutical exports exceeded US$30 billion in FY25. 

The domestic pharmaceutical market is expected to witness healthy long-term growth driven by chronic disease treatments, healthcare awareness, and rising penetration in rural markets. Increased investments in API manufacturing, biotechnology, and specialty medicines are also expected to support future industry expansion. 

Morepen Laboratories delivered stable revenue growth during Q4 FY26, although profitability remained under pressure due to weaker margins and higher operational costs. The company’s dividend announcement and continued presence in domestic as well as export markets remain positive indicators for investors. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Morepen Laboratories Shares Plummet 5% as Q4 Earnings Decline 48% QoQ; Announces 10% Final Dividend  appeared first on Trade Brains.